Author

Nicole C.H.P. de Graauw

Observed names: N. C. de Graauw, N.C.H.P. de Graauw, N.C.H.P. van der Burg-De Graauw, N.C.H.P. van der Burg-de Graauw, Nicole C H P van der Burg-de Graauw, Nicole C. H. P. de Graauw, Nicole C. H. P. van der Burg-de Graauw, Nicole C.H.P. van der Burg-de Graauw, Nicole C.H.P. van der Burg‐de Graauw, Nicole de Graauw

Institution: Bravis Ziekenhuis

Observed institutions: Noordwest Ziekenhuisgroep, Amphia Ziekenhuis, Amsterdam University Medical Centers, Bravis Ziekenhuis, Cancer Center Amsterdam, Vrije Universiteit Amsterdam

ORCID: 0000-0001-6147-0856

Observed ORCID: 0000-0001-6147-0856

OpenAlex ID: A5079135391

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

2021 · Claudia A. M. Stege, Kazem Nasserinejad, et al. · Journal of Clinical Oncology · 68

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study

2018 · Femke M. de Man, Koen G.A.M. Hussaarts, et al. · Clinical Pharmacology & Therapeutics · 22

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

2019 · Claudia A.M. Stege, Kazem Nasserinejad, et al. · Blood · 16

Improving the identification of frail elderly newly diagnosed multiple myeloma patients

2021 · Claudia A. M. Stege, Kazem Nasserinejad, et al. · Leukemia · 11

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

2024 · Febe Smits, Kaz Groen, et al. · Blood · 10

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

2023 · Febe Smits, Kaz Groen, et al. · Blood · 7

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial

2025 · Febe Smits, Kaz Groen, et al. · Blood Advances · 6

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial

2024 · M.R. Seefat, C.A.M. Stege, et al. · European Journal of Cancer · 6

[Fatal pulmonary tumour embolism as initial manifestation of an occult coecum tumour].

2009 · Nicole C H P van der Burg-de Graauw, Joost W J van Esser · PubMed · 2

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

2024 · Febe Smits, Kaz Groen, et al. · Blood · 1

P906: Ixazomib, Daratumumab and Low Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma (ndmm): Results of the Maintenance Treatment of the Phase Ii Hovon 143 Study

2022 · K. Groen, M. Seefat, et al. · HemaSphere · 1

Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib

2018 · F.M. de Man, K.G.A.M. Hussaarts, et al. · Annals of Oncology · 1

Home-based treatment for multiple myeloma patients: early insights from a pilot project

2026 · Saskia Claassen, Damien S E Broekharst, et al. · British Journal of Healthcare Management

P12 Health-related Quality of Life in Frail and Intermediate-fit Patients With Newly Diagnosed Multiple Myeloma Treated With Dose-adjusted Melphalan-prednisone-bortezomib (mpv)

2023 · M.R. Seefat, C.A.M. Stege, et al. · HemaSphere

Works count: 14

Citation count: 151

H-index: 6

I10-index: 5